DataMEDS Acquires Helomics for $1.5 Million, Expanding into Cancer Diagnostics
DataMEDS AI has completed its acquisition of Helomics Corporation from Axe Compute in a deal valued at $1.5 million. The transaction includes DataMEDS issuing common shares and an acquisition note while also receiving $1.5 million in cash as part of the agreement. Helomics brings with it a CLIA/CAP-certified clinical laboratory, equipment, and Predictive Oncology's contract research organization (CRO) central lab services business. The move allows DataMEDS to expand into cancer diagnostics by leveraging Helomics' AI-based precision oncology platform that analyzes real-world tumor data for drug discovery and treatment decisions. The acquisition is expected to enable the company to offer new services such as cancer screening, molecular profiling, traditional clinical laboratory tests, and nutritional support for patients. For Axe Compute shareholders, this transaction marks a strategic exit from its remaining cancer testing operations following a name change in December 2025. While no revenue targets or timelines were disclosed, the deal could enhance DataMEDS' healthcare ecosystem by integrating Helomics into existing services like pharmacy and telemedicine.
Topics: AI in Healthcare Cancer Diagnostics Company Acquisition